A new trading day began on Friday, with Lyra Therapeutics Inc (NASDAQ: LYRA) stock price down -0.98% from the previous day of trading, before settling in for the closing price of $0.11. LYRA’s price has ranged from $0.08 to $0.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 78.20% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 55.94%. With a float of $55.76 million, this company’s outstanding shares have now reached $65.88 million.
In an organization with 30 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1019.32%, operating margin of -6891.56%, and the pretax margin is -6708.95%.
Lyra Therapeutics Inc (LYRA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lyra Therapeutics Inc is 16.73%, while institutional ownership is 36.55%. The most recent insider transaction that took place on Apr 25 ’25, was worth 14,930. Before that another transaction happened on Apr 09 ’25, when Company’s Officer proposed sale 39,567 for $0.09, making the entire transaction worth $3,545.
Lyra Therapeutics Inc (LYRA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 55.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.95% during the next five years compared to -2.22% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Here are Lyra Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Let’s dig in a bit further. During the last 5-days, its volume was 17.91 million. That was better than the volume of 2.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.47%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 18.22%, which indicates a significant decrease from 28.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.22% in the past 14 days, which was higher than the 90.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1240, while its 200-day Moving Average is $0.2066. However, in the short run, Lyra Therapeutics Inc’s stock first resistance to watch stands at $0.1311. Second resistance stands at $0.1506. The third major resistance level sits at $0.1611. If the price goes on to break the first support level at $0.1011, it is likely to go to the next support level at $0.0906. The third support level lies at $0.0711 if the price breaches the second support level.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
With a market capitalization of 7.40 million, the company has a total of 66,267K Shares Outstanding. Currently, annual sales are 1,530 K while annual income is -93,440 K. The company’s previous quarter sales were 180 K while its latest quarter income was -8,550 K.
